Nutriband Reports Record Q1 Revenue, Advances Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. reported a 63% year-over-year revenue increase in Q1, driven by expanded kinesiology tape production and retail presence, while simultaneously progressing its AVERSA Fentanyl patch development through a strategic partnership with Kindeva Drug Delivery.
Nutriband Inc. (NASDAQ: NTRB) announced strong first-quarter financial results, with revenue reaching $667,000, representing a 63% increase compared to the same period last year. The company's growth is attributed to expanded kinesiology tape production through its Pocono Pharma subsidiary and an increased retail presence at major retailers including Target, Walmart, Walgreens, and CVS.
The pharmaceutical development company is simultaneously advancing its AVERSA Fentanyl patch, an abuse-deterrent transdermal opioid treatment. A newly established partnership with Kindeva Drug Delivery will support shared development costs and provide milestone payments as the product progresses toward regulatory approval. Market projections suggest the patch could generate between $80 million and $200 million in annual U.S. sales.
Nutriband's AVERSA technology represents a significant innovation in pharmaceutical development, designed to prevent drug abuse, misuse, diversion, and accidental exposure. The technology can be incorporated into transdermal patches to enhance patient safety and reduce potential opioid-related risks.
The company's strategic approach of scaling Pocono Pharma's output through penetration pricing while simultaneously developing advanced pharmaceutical solutions demonstrates a commitment to both immediate revenue growth and long-term innovation in the healthcare sector.